Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD.
Listed on Nasdaq First North Growth Market.
Company Details
- Employees
- 15
- Address
- Nybrogatan 34, Stockholm,sweden
- Phone
- +46 46-286 50 30
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- guardtherapeutics.com
- HQ
- Stockholm
Guard Therapeutics Questions
Guard Therapeutics's helpline number is +46 46-286 50 30
Guard Therapeutics's website is guardtherapeutics.com
Guard Therapeutics's LinkedIn profile is https://se.linkedin.com/company/guard-therapeutics
Guard Therapeutics has
15 employees.
View email and phone details for 15
employees at Guard Therapeutics.
Guard Therapeutics's industry is
Biotechnology Research
Guard Therapeutics's top competitors are
Buzzard Pharmaceuticals,
Pixelgen Technologies,
Neuro-Innovators, Inc.,
Lipum Ab,
Diamyd Medical,
Cantargia Ab,
D2team,
Advicenne Inc.,
Amalus Therapeutics,
Averoa.
Guard Therapeutics's support email address is info@guardtherapeutics.com
Guard Therapeutics's categories are Biotechnology Research
